Patents by Inventor Anita Kavlie

Anita Kavlie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION
    Publication number: 20240092938
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Application
    Filed: February 13, 2023
    Publication date: March 21, 2024
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
    Publication number: 20230399391
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: January 5, 2023
    Publication date: December 14, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine lmhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2
    Publication number: 20230227543
    Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: March 31, 2023
    Publication date: July 20, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thoms Regula, Werner Scheuer
  • Compositions for inhibiting MASP-2 dependent complement activation
    Patent number: 11613589
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: March 28, 2023
    Assignee: OMEROS CORPORATION
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2
    Publication number: 20210388071
    Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: April 5, 2021
    Publication date: December 16, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
  • COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION
    Publication number: 20210054099
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Application
    Filed: April 24, 2020
    Publication date: February 25, 2021
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
    Publication number: 20210047394
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: March 13, 2020
    Publication date: February 18, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2
    Publication number: 20200262904
    Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: September 26, 2019
    Publication date: August 20, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
  • Compositions for inhibiting MASP-2 dependent complement activation
    Patent number: 10683367
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: June 16, 2020
    Assignee: Omeros Corporation
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • Compositions for Inhibiting MASP-2 Dependent Complement Activation
    Publication number: 20190119402
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Application
    Filed: July 13, 2018
    Publication date: April 25, 2019
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2
    Publication number: 20180282404
    Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: February 28, 2018
    Publication date: October 4, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
  • Compositions for inhibiting MASP-2 dependent complement activation
    Patent number: 10047165
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: August 14, 2018
    Assignee: Omeros Corporation
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
    Publication number: 20170369566
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: May 23, 2017
    Publication date: December 28, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
    Publication number: 20170240626
    Abstract: The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: October 4, 2016
    Publication date: August 24, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Kay-Gunnar Stubenrauch, Markus Thomas
  • Bispecific anti-VEGF/anti-ANG-2 antibodies
    Patent number: 9708396
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: July 18, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION
    Publication number: 20170088632
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Application
    Filed: September 13, 2016
    Publication date: March 30, 2017
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2
    Publication number: 20170029493
    Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: April 12, 2016
    Publication date: February 2, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
  • Compositions for inhibiting MASP-2 dependent complement activation
    Patent number: 9475885
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: October 25, 2016
    Assignee: Omeros Corporation
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • ANTIBODIES
    Publication number: 20160244527
    Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Application
    Filed: May 11, 2016
    Publication date: August 25, 2016
    Applicant: AFFITECH RESEARCH AS
    Inventors: Anita KAVLIE, Sergej Michailovic KIPRIJANOV
  • Anti-VEGF antibody compositions and methods
    Patent number: 9421256
    Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: August 23, 2016
    Assignees: Affitech Research AS, Peregrine Pharmaceuticals, Inc.
    Inventors: Anita Kavlie, Kyle Schlunegger